Page 126 - SRPSKO DRUŠTVO ISTRAŽIVAČA RAKA

Serbian Association for Cancer Research SDIRSACR

polymorphisms was observed in terms of overall survival in CRC patients (p˃0.05).
Conclusions: Our results suggest that GSTO1 and GSTO2 polymorphisms may confer CRC risk.

P30

A Case of Hereditary Hemorrhagic Telangiectasis

Osman Akidan

Department of Hematology, Mengucek Gazi Education and Research Hospital, Erzincan, Turkey

Keywords: Bevacizumab, Bleeding, Hereditary hemorrhagic telangiectasia

Background: Hereditary hemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu disease) is a multisystemic
vascular disorder characterized by abnormal angiogenesis and inherited in an autosomal dominant manner. HHT is
the second most common hereditary bleeding disorder worldwide. It affects approximately 1 in 5,000 individuals, or
an estimated 1.4 million people globally, making it twice as prevalent as hemophilia A and 12 times more common
than hemophilia B. HHT is characterized by vascular malformations in the nasal mucosa, skin, gastrointestinal tract,
brain, lungs, and liver, and leads to telangiectasia in the nasal mucosa, resulting in recurrent epistaxis. This condition
is observed in approximately 95% of HHT patients, with the average age of onset around 12 years and an epistaxis
frequency of approximately 18 episodes per month.
Patient: A 76-year-old male patient has experienced epistaxis since the age of 10 and oral bleeding for the past 4
years. The patient underwent inguinal hernia surgery in 1995 and a gastric biopsy in 2023, during which no hemostatic
complications were observed. He has a history of enoxaparin and warfarin (Coumadin) use due to atrial fibrillation.
The patient has recurrent episodes of epistaxis and oral bleeding approximately every two weeks and a history of
frequent erythrocyte transfusions. His hemoglobin levels have remained around 7 mg/dL. On December 8, 2023,
bevacizumab therapy (anti-VEGF monoclonal antibody) was initiated at a dose of 5 mg/kg every two weeks. By the first
month of treatment, his hemoglobin level had increased to 10 mg/dL, and by the second month, to 12 mg/dL. When
bevacizumab therapy was temporarily discontinued, bleeding episodes recurred; therefore, it was decided to continue
maintenance therapy at intervals of once every three weeks.
Conclusion: This case demonstrates that epistaxis, one of the hallmark symptoms of HHT, can begin in childhood
and persist into advanced age. Following bevacizumab therapy, a significant improvement in hemoglobin levels was
achieved; however, bleeding recurred upon discontinuation of the treatment. This finding supports the potential
efficacy of anti-VEGF therapy in managing HHT-related bleeding. Furthermore, treatment planning should be carried
out with caution, considering comorbid conditions such as the use of anticoagulants.

P31

XRCC1 1196A>G and RAD51 135G>C polymorphic variants in rectal cancer: significance for cancer risk
and response to chemoradiotherapy

Teodora Ćato , Aleksandra Stanojević , Miodrag Vuković , Ana Ećim , Vladimir Nikolić , Mladen Marinković , Suzana
1
1
2
3,4
1
1
Stojanović-Rundić , Radmila Janković , Milena Čavić 1
3,4
1
1Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia
2Clinic for Medical Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia
3Clinic for Radiation Oncology and Diagnostics, Department of Radiation Oncology, Institute for Oncology and Radiology of
Serbia, Pasterova 14, 11000 Belgrade, Serbia
4Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia
Keywords: Chemoradiotherapy, Polymorphism, single nucleotide, RAD51 recombinase, Rectal neoplasms, X-ray repair
cross complementing protein 1
Background: X-ray repair cross-complementing protein 1 (XRCC1) and DNA repair protein RAD51 homolog 1 (Rad51)

111